Healthy Clinical Trial
Official title:
A Pilot Study in Healthy Volunteers of McKay Airway - An Improved Oral Airway for Awake Fibre-optic Intubation
When endotracheal intubation is known or predicted to be difficult, patients are intubated
awake using a flexible bronchoscope (awake fibre-optic intubation: AFI) so that they can
protect their airway with normal upper airway muscle activity until the endotracheal tube
(ETT) is safely in place. New bite blocks have been invented for bag mask ventilation but are
not suitable for AFI.1 A newly invented airway device, the McKay airway, may provide a better
solution for AFI by enabling jaw thrust, a condition where the upper airway is opened more as
the jaw is protruded forward. It may also be more comfortable for awake users. A study is
proposed to assess the functionality of the device for this purpose.
To protect the bronchoscope, a bite block is used during AFI to protect the very delicate
glass fibres from damage from inadvertent biting by the patient. Currently used bite blocks
protect the scope, but do not position the jaw optimally for scoping. The proposed device is
an attempt to improve upon current bite blocks by both protecting the bronchoscope and
positioning the jaw optimally.
Hypothesis: Residents in training in the Division of Respirology have limited experience in
fibre-optic bronchoscopy and perform it under the direct supervision of an expert. Null
hypothesis: the time to visualization of vocal cords with a fibre-optic bronchoscope by
residents learning in the Division of Respirology will be no different with the McKay airway
than with the conventional bite block or Williams Airway.
INTRODUCTION When endotracheal intubation is known or predicted to be difficult, patients are
intubated awake using a flexible bronchoscope so that they can protect their airway with
normal upper airway muscle activity until the endotracheal tube (ETT) is safely in place. A
newly invented airway device, the McKay airway, (Appendix 2) may provide a better solution to
placing an ETT into the windpipe of an awake patient, (awake fibre-optic intubation: AFI) A
study is proposed to assess the functionality of the device for this purpose.
To protect the bronchoscope, a bite block is used during AFI to protect the very delicate
glass fibres from damage from inadvertent biting by the patient. Currently used bite blocks
(Appendix 2, figure 5) protect the scope, but do not position the jaw or bronchoscope
optimally for scoping. This is not a problem for experienced bronchoscopists such as
respirologists, but can be for those, like anesthesiologists, who do bronchoscopy
infrequently. For these, the proposed device may be an improvement upon current bite blocks.
Hypothesis: Residents in training in the Division of Respirology have limited experience in
fibre-optic bronchoscopy and perform it under the direct supervision of an expert. Null
hypothesis: the time to visualization of vocal cords with a fibre-optic bronchoscope by
residents learning in the Division of Respirology will be no different with the McKay airway
than with the conventional bite block.
Experimental design: The proposed experiment is an unblinded repeated measures interventional
clinical trial with concealed randomization of which device is used first and which second.
Randomization will be by a computer-generated random number table (1s and 2s where 1 is
conventional bite block is used first and 2 means McKay airway first) transcribed to paper
cards in numbered opaque envelopes to be opened just prior to bronchoscopy.
Primary outcome: Time from beginning insertion of bronchoscope into the bite block to
visualization of vocal cords.
Secondary outcomes: Scores will be recorded on rating scales for: ease of insertion, ease of
obtaining proper position of teeth in the device by patients, assessment of gag reflex.
Comments about overall impression will be recorded.
Participants: Participants are of two kinds, patients and residents. Patients will be
consenting patients booked for bronchoscopy by pulmonologists at Royal University Hospital.
Excepted patients will be those who do not wish to participate and those with any health
conditions that the attending pulmonologist feels puts them at any added risk by
participating.
Consent: With University of Saskatchewan Research Ethics Board approval, the investigators
will recruit patients and obtain signed informed consent at the time of booking bronchoscopy
or on arrival for bronchoscopy.
Data and privacy concerns: As well as the primary and secondary outcomes, data collection on
paper data sheets will include basic demographics. These are: age, gender, height, weight,
and diagnosis as well as airway characteristics (see Appendix 1, Data Sheet). Because this
may identify patients and breach their privacy, the data sheets will be identified only by
number. The de-identified data collection sheets will be labeled with a unique numerical
identifier (e.g., 1, 2, 3, etc). The data collection sheet will be linked to the patient
Personal Health Number by way of a physically separate Master Data list (e.g., 1, 2, 3,
etc.). (See attached - Master Data List) The de-identified data from the data collection
sheet (See Attached - Data Collection Sheet) will be transcribed by Dr. McKay to data base on
a password protected computer kept in a locked office in the Department of Anesthesiology at
all times. Identifiable patient information will not be transcribed electronically. Upon
completion of the study, Dr McKay will store electronic data files and paper forms in a
locked filing cabinet in the Department of Anesthesiology (accessible only by key code), as
per the University of Saskatchewan Research Integrity Policy
(http://www.usask.ca/university_secretary/policies/research/8_25.php). The Master Data List
(paper only) will be stored in a physically separate location from the data collection forms.
The hard copies of the data collection forms, master list, and completed consent forms will
be destroyed through the confidential paper disposal services of the SHR, while the
electronic data will be permanently deleted after 5 years as per the above University of
Saskatchewan Research Integrity Policy. We anticipate this data to be the basis for a
publication in a peer-reviewed scientific journal and at a national scientific meeting.
Patient safety: The experiment will be overseen by the attending specialist respirologist who
will intervene immediately as needed and proceed as clinically indicated if any issue of
patient safety arises at any time. This is normal practice. We expect that risk to
participating patients is minimal. We anticipate the following incidence: 1) common (1-10%)
side effects: none. 2) uncommon (0.1 to 1%) side effects: mild abrasion of the mouth (which
can occur with the currently available awake intubation bite blocks and airways as often). 3)
rare (0.01-0.1%) side effects: zero. 4) Very rare (<0.01%) side effects: sensitivity to the
plastic with irritation of the oral mucosa (which can occur with the currently available
awake intubation plastic bite blocks and airways as often). The McKay airway is made of
medical grade plastic. 5) Severe side effects: zero (prolonged hospital admission, admission
to intensive care, loss of limb or vital organ, or death). We believe that risk of
participation is not different from risk of bronchoscopy, and is safe in expert hands.
Measurements. With a stopwatch, the investigator will measure the time from beginning to
place the bronchoscope in the mouth following topicalization to visualization of vocal cords
or epiglottis. Following bronchoscopy, the Respirologist will rate the modalities with rating
scales (see attached Data Sheet).
Number of participants: There is no similar study from which to calculate sample size. We
will initially assuming that one modality is 0.2 times faster with standard deviation 0.2,
paired t-test sample size is calculated at n = 10, then recalculate based on the primary
outcome findings.
Statistical analysis. Demographic and rating data will be tabulated as observational; time
measurements compared by paired t-test or Mann-Whitney U test as mean ± standard deviation
and [95% Confidence Intervals] or median and [interquartile range] as appropriate following a
Kolmogorov-Smirnov test of normality.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |